Prudential Financial Inc. reduced its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 2.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 283,311 shares of the medical instruments supplier’s stock after selling 7,160 shares during the period. Prudential Financial Inc. owned 0.76% of AngioDynamics worth $5,578,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. Systematic Financial Management LP raised its holdings in AngioDynamics by 586.4% in the second quarter. Systematic Financial Management LP now owns 380,622 shares of the medical instruments supplier’s stock valued at $7,494,000 after buying an additional 325,172 shares during the period. Shell Asset Management Co. purchased a new position in AngioDynamics in the first quarter valued at approximately $621,000. Penn Capital Management Co. Inc. raised its holdings in AngioDynamics by 25.6% in the first quarter. Penn Capital Management Co. Inc. now owns 128,364 shares of the medical instruments supplier’s stock valued at $2,934,000 after buying an additional 26,185 shares during the period. Keybank National Association OH raised its holdings in AngioDynamics by 41.8% in the second quarter. Keybank National Association OH now owns 66,670 shares of the medical instruments supplier’s stock valued at $1,313,000 after buying an additional 19,650 shares during the period. Finally, Campbell & CO Investment Adviser LLC raised its holdings in AngioDynamics by 104.9% in the first quarter. Campbell & CO Investment Adviser LLC now owns 34,293 shares of the medical instruments supplier’s stock valued at $784,000 after buying an additional 17,553 shares during the period. Institutional investors and hedge funds own 99.51% of the company’s stock.

In other news, Director Kevin J. Gould sold 13,650 shares of AngioDynamics stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $21.45, for a total transaction of $292,792.50. Following the sale, the director now owns 61,774 shares in the company, valued at $1,325,052.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 3.60% of the company’s stock.

Shares of ANGO traded up $0.10 during mid-day trading on Friday, reaching $18.49. 16,875 shares of the stock traded hands, compared to its average volume of 139,695. The firm has a market cap of $679.65 million, a price-to-earnings ratio of 22.28 and a beta of 0.72. The stock has a fifty day simple moving average of $19.22 and a 200 day simple moving average of $20.45. AngioDynamics, Inc. has a 12-month low of $17.67 and a 12-month high of $25.48. The company has a quick ratio of 3.75, a current ratio of 4.30 and a debt-to-equity ratio of 0.20.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Wednesday, July 10th. The medical instruments supplier reported $0.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.01). The firm had revenue of $96.30 million for the quarter, compared to analysts’ expectations of $92.34 million. AngioDynamics had a net margin of 17.06% and a return on equity of 5.58%. The company’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.20 EPS. On average, equities research analysts expect that AngioDynamics, Inc. will post 0.27 earnings per share for the current fiscal year.

Several research firms recently commented on ANGO. Zacks Investment Research upgraded shares of AngioDynamics from a “sell” rating to a “hold” rating and set a $20.00 price target on the stock in a report on Tuesday, June 4th. TheStreet lowered shares of AngioDynamics from a “b” rating to a “c” rating in a research note on Monday, July 29th. ValuEngine upgraded shares of AngioDynamics from a “hold” rating to a “buy” rating in a research note on Tuesday, July 2nd. Finally, BidaskClub lowered shares of AngioDynamics from a “hold” rating to a “sell” rating in a research note on Saturday, August 31st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the stock. AngioDynamics currently has a consensus rating of “Hold” and a consensus price target of $21.50.

AngioDynamics Profile

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

Featured Story: What does EPS mean?

Institutional Ownership by Quarter for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.